24th Jun 2025 Plain language summary: two key studies on acalabrutinib’s efficacy and safety profile for treating patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma
13th Mar 2025 A plain language summary of the ELEVATE-TN study: Chemotherapy-free treatment with acalabrutinib for previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
28th Feb 2023 Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years: a plain language summary
